Paper3697995
Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function.
D'Incalci M and 7 others. Cancer Res, 1986. Cited by 101 papers, by iCite.
Cite this record
ConductScience Library. Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Papers, record 3697995. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3697995
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Etoposide | Major topic |
| Kidney Diseases | Major topic |
| Liver Diseases | Major topic |
| Podophyllotoxin | Major topic |
| Adult | |
| Aged | |
| Female | |
| Humans | |
| Male | |
| Metabolic Clearance Rate | |
| Middle Aged |
Source PubMed
Cited by25
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 101 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 32676789 | Pharmacokinetic and Pharmacogenetic Study of Etoposide in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors. | Pharm Res | 2020 | https://conductscience.org/library/papers/32676789 | PubMed |
| 30947665 | Decreased Disposition of Anticancer Drugs Predominantly Eliminated via the Liver in Patients with Renal Failure. | Curr Drug Metab | 2019 | https://conductscience.org/library/papers/30947665 | PubMed |
| 30328531 | Influence of UGT1A1 polymorphism on etoposide plus platinum-induced neutropenia in Japanese patients with small-cell lung cancer. | Int J Clin Oncol | 2019 | https://conductscience.org/library/papers/30328531 | PubMed |
| 30261554 | Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function. | Br J Clin Pharmacol | 2019 | https://conductscience.org/library/papers/30261554 | PubMed |
| 29209521 | Management of patients with end-stage renal disease undergoing chemotherapy: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Nefrologia (SIN). | ESMO Open | 2017 | https://conductscience.org/library/papers/29209521 | PubMed |
| 23968328 | Acute myeloid leukemia in a 38-year-old hemodialyzed patient with von Hippel-Lindau disease. | Hered Cancer Clin Pract | 2013 | https://conductscience.org/library/papers/23968328 | PubMed |
| 21298312 | Successful treatment of acute promyelocytic leukemia in a patient on hemodialysis. | Clin Exp Nephrol | 2011 | https://conductscience.org/library/papers/21298312 | PubMed |
| 16752933 | Dose adaptation of antineoplastic drugs in patients with liver disease. | Drug Saf | 2006 | https://conductscience.org/library/papers/16752933 | PubMed |
| 16524321 | Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile. | Drug Saf | 2006 | https://conductscience.org/library/papers/16524321 | PubMed |
| 15170366 | Effect of haemodialysis on the pharmacokinetics of antineoplastic drugs. | Clin Pharmacokinet | 2004 | https://conductscience.org/library/papers/15170366 | PubMed |
| 15139794 | Pharmacokinetic optimisation of treatment with oral etoposide. | Clin Pharmacokinet | 2004 | https://conductscience.org/library/papers/15139794 | PubMed |
| 12448655 | Phase I escalation of gemcitabine combined with protracted oral etoposide in gynecologic malignancies: A Gynecologic Oncology Group study. | Invest New Drugs | 2002 | https://conductscience.org/library/papers/12448655 | PubMed |
| 11736859 | Population pharmacokinetics and pharmacodynamics of oral etoposide. | Br J Clin Pharmacol | 2001 | https://conductscience.org/library/papers/11736859 | PubMed |
| 8611379 | Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal dialysis and haemodialysis. | Br J Cancer | 1996 | https://conductscience.org/library/papers/8611379 | PubMed |
| 8431968 | Pharmacokinetics of etoposide: correlation of pharmacokinetic parameters with clinical conditions. | Cancer Chemother Pharmacol | 1993 | https://conductscience.org/library/papers/8431968 | PubMed |
| 8070032 | Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations. | Cancer Chemother Pharmacol | 1994 | https://conductscience.org/library/papers/8070032 | PubMed |
| 7961107 | In vitro and in vivo effects of cisplatin and etoposide in combination on small cell lung cancer cell lines. | Jpn J Cancer Res | 1994 | https://conductscience.org/library/papers/7961107 | PubMed |
| 7497587 | Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer. | Cancer Chemother Pharmacol | 1995 | https://conductscience.org/library/papers/7497587 | PubMed |
| 3555940 | Pharmacokinetics of anticancer drugs in children. | Clin Pharmacokinet | 1987 | https://conductscience.org/library/papers/3555940 | PubMed |
| 3047665 | Etoposide and teniposide. Bioanalysis, metabolism and clinical pharmacokinetics. | Pharm Weekbl Sci | 1988 | https://conductscience.org/library/papers/3047665 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/3697995
GET https://conductscience.org/api/papers/v1/3697995/cited_by?page=2